= 871038-72-1 反应条件:1.1 -1.2 Reagents: Potassium Hydroxide Solvents: Ethanol2.1 Reagents: Oxalyl Chloride Catalysts: Dimethylformamide Solvents: Acetonitrile3.1 Reagents: 4-Methylmorpholine Solvents: Acetonitrile3.2 Reagents: Potassium Hydroxide Solvents: Acetic Acid 标题:Identification,Synthesis,And Strategy For Minimization Of Potential Impurities Observed In Raltegravir Potassium Drug Substance 作者:Patil,Gulabrao D.; Et Al 参考文献:Organic Process Research & Development 日期:2012 卷标:16(8) 页码:1422-1429]
140-75-0 + 888504-27-6 = 871038-72-1 反应条件:1.1 -2.1 Reagents: Triethylamine,4-(Dimethylamino)Pyridine2.2 Reagents: Glycolic Acid,Hydrogen Catalysts: Palladium Solvents: Methanol2.3 Reagents: Triethylamine3.1 Reagents: 4-Methylmorpholine Solvents: Acetonitrile3.2 Reagents: Potassium Hydroxide Solvents: Acetic Acid 标题:Identification,Synthesis,And Strategy For Minimization Of Potential Impurities Observed In Raltegravir Potassium Drug Substance 作者:Patil,Gulabrao D.; Et Al 参考文献:Organic Process Research & Development 日期:2012 卷标:16(8) 页码:1422-1429]
762-42-5 + 518047-98-8 = 871038-72-1 反应条件:1.1 -2.1 Reagents: Magnesium Hydroxide Solvents: N-Methyl-2-Pyrrolidone,Water3.1 -4.1 Reagents: Triethylamine,4-(Dimethylamino)Pyridine4.2 Reagents: Glycolic Acid,Hydrogen Catalysts: Palladium Solvents: Methanol4.3 Reagents: Triethylamine5.1 Reagents: 4-Methylmorpholine Solvents: Acetonitrile5.2 Reagents: Potassium Hydroxide Solvents: Acetic Acid 标题:Identification,Synthesis,And Strategy For Minimization Of Potential Impurities Observed In Raltegravir Potassium Drug Substance 作者:Patil,Gulabrao D.; Et Al 参考文献:Organic Process Research & Development 日期:2012 卷标:16(8) 页码:1422-1429]
100134-82-5 = 871038-72-1 反应条件:1.1 Reagents: Hydroxylamine Solvents: Isopropanol2.1 -3.1 Reagents: Magnesium Hydroxide Solvents: N-Methyl-2-Pyrrolidone,Water4.1 -5.1 Reagents: Triethylamine,4-(Dimethylamino)Pyridine5.2 Reagents: Glycolic Acid,Hydrogen Catalysts: Palladium Solvents: Methanol5.3 Reagents: Triethylamine6.1 Reagents: 4-Methylmorpholine Solvents: Acetonitrile6.2 Reagents: Potassium Hydroxide Solvents: Acetic Acid 标题:Identification,Synthesis,And Strategy For Minimization Of Potential Impurities Observed In Raltegravir Potassium Drug Substance 作者:Patil,Gulabrao D.; Et Al 参考文献:Organic Process Research & Development 日期:2012 卷标:16(8) 页码:1422-1429]
1172131-64-4 + 889131-28-6 = 871038-72-1 反应条件:1.1 Reagents: 4-Methylmorpholine Solvents: Acetonitrile1.2 Reagents: Potassium Hydroxide Solvents: Acetic Acid 标题:Identification,Synthesis,And Strategy For Minimization Of Potential Impurities Observed In Raltegravir Potassium Drug Substance 作者:Patil,Gulabrao D.; Et Al 参考文献:Organic Process Research & Development 日期:2012 卷标:16(8) 页码:1422-1429]
888504-28-7 + 518048-02-7 = 871038-72-1 [标题:Reaction Conditions 标题:Crystalline Forms Of N-(2-(4-(4-Fluorobenzylcarbamoyl)-5-Hydroxy-1-Methyl-6-Oxo-1,6-Dihydropyrimidin-2-Yl)Propan-2-Yl)-5-Methyl-1,3,4-Oxadiazole-2-Carboxamide Intermediates 作者:Anonymous 参考文献:Ip.Com Journal 日期:2014 卷标:14 页码:1-6]
518048-02-7 = 871038-72-1 反应条件:1.1 Reagents: Triethylamine,4-(Dimethylamino)Pyridine1.2 Reagents: Glycolic Acid,Hydrogen Catalysts: Palladium Solvents: Methanol1.3 Reagents: Triethylamine2.1 Reagents: 4-Methylmorpholine Solvents: Acetonitrile2.2 Reagents: Potassium Hydroxide Solvents: Acetic Acid 标题:Identification,Synthesis,And Strategy For Minimization Of Potential Impurities Observed In Raltegravir Potassium Drug Substance 作者:Patil,Gulabrao D.; Et Al 参考文献:Organic Process Research & Development 日期:2012 卷标:16(8) 页码:1422-1429]
专利号:US-2025206743-A1 优先权日:2022-03-25 标 题:Tyk2 inhibitor synthesis and intermediates thereof 发明人:MASSE CRAIG E; PHADKE AVINASH S; LAWSON JON P; LEVY STUART; YANG XIAOWEI; WU GUISHENG; FAN SHUFENG 权利人:TAKEDA PHARMACEUTICALS CO 摘要:Described herein are methods of synthesis of a tyrosine-protein kinase 2 (TYK2) inhibitor and to intermediate compounds of the synthesis and methods of making the intermediates. Also provided are pharmaceutically acceptable compositions including compounds prepared by the synthetic method and methods of treating disorders using the same.
1: Brogan AJ, Davis AE, Goodwin B. Short-term cost analysis of raltegravir versus atazanavir + ritonavir or darunavir + ritonavir for treatment-naive adults with HIV-1 infection in the United States. PLoS One. 2018 Aug 30;13(8):e0203293. doi: 10.1371/journal.pone.0203293. eCollection 2018. 2: Trahan MJ, Lamarre V, Metras ME, Kakkar F. Use of Triple Combination Antiretroviral Therapy With Raltegravir as Empiric HIV Therapy in the High-Risk HIV-Exposed Newborn. Pediatr Infect Dis J. 2018 Aug 27. doi: 10.1097/INF.0000000000002180. [Epub ahead of print] Patient Self-Reported Adherence to Ritonavir-Boosted Darunavir Combined with Either Raltegravir or Tenofovir Disoproxil Fumarate /Emtricitabine in the Neat 001/Anrs 143 Trial. J Acquir Immune Defic Syndr. 2018 Aug 27. doi: 10.1097/QAI.0000000000001834. [Epub ahead of print] doi: 10.5114/aoms.2016.62445. Epub 2016 Sep 22. 7: Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006-. Available from http://www.ncbi.nlm.nih.gov/books/NBK501554/ doi: 10.1016/j.msard.2018.06.002. Epub 2018 Jun 28. Blood Telomere Length Changes after Ritonavir-boosted Darunavir Combined with Raltegravir or Tenofovir-Emtricitabine in Antiretroviral-Naive Adults Infected with HIV-1. J Infect Dis. 2018 Jul 3. doi: 10.1093/infdis/jiy399. [Epub ahead of print] doi: 10.1111/hiv.12636. Epub 2018 Jul 3. Dolutegravir (DTG)-containing regimens after receiving raltegravir (RAL) or elvitegravir (EVG): Durability and virological response in a large Italian HIV drug resistance network (ARCA). J Clin Virol. 2018 Aug;105:112-117. doi: 10.1016/j.jcv.2018.06.012. Epub 2018 Jun 21. doi: 10.1099/jgv.0.001090. Epub 2018 Jun 19. Raltegravir plus abacavir/lamivudine in virologically suppressed HIV-1-infected patients: 48-week results of the KIRAL study. PLoS One. 2018 Jun 14;13(6):e0198768. doi: 10.1371/journal.pone.0198768. eCollection 2018.
合成参考文献
参考文献:10.1086/650749 摘要:McMahon D, Jones J, Wiegand A, Gange SJ, Kearney M, Palmer S, McNulty S, Metcalf JA, Acosta E, Rehm C, Coffin JM, Mellors JW, Maldarelli F. Short-course raltegravir intensification does not reduce persistent low-level viremia in patients with HIV-1 suppression during receipt of combination antiretroviral therapy. Clin Infect Dis. 2010 Mar 15;50(6):912–9. 参考文献:10.1128/aac.00593-11 摘要:Wang L, Soon GH, Seng KY, Li J, Lee E, Yong EL, Goh BC, Flexner C, Lee L. Pharmacokinetic modeling of plasma and intracellular concentrations of raltegravir in healthy volunteers. Antimicrob Agents Chemother. 2011 Sep;55(9):4090–5. 参考文献:10.1182/blood-2011-05-351155 摘要:Lugli E, Mueller YM, Lewis MG, Villinger F, Katsikis PD, Roederer M. IL-15 delays suppression and fails to promote immune reconstitution in virally suppressed chronically SIV-infected macaques. Blood. 2011 Sep 01;118(9):2520–9. 参考文献:10.1111/j.1365-2516.2011.02610.x 摘要:Mangiafico L, Perja M, Fusco F, Riva S, Mago D, Gringeri A. Safety and effectiveness of raltegravir in patients with haemophilia and anti-HIV multidrug resistance. Haemophilia. 2012 Jan;18(1):108–11. doi: 10.1111/j.1365-2516.2011.02610.x.